Breast cancer management

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy (surgery and radiotherapy) and systemic treatment (chemo-, endocrine, and targeted therapies). Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

Historically, breast cancer was treated with radical surgery alone. Advances in the understanding of the natural course of breast cancer as well as the development of systemic therapies allowed for the use of breast-conserving surgeries, however, the nomenclature of viewing non-surgical management from the viewpoint of the definitive surgery lends to two adjectives connected with treatment timelines: adjuvant (after surgery) and neoadjuvant (before surgery).

The mainstay of breast cancer management is surgery for the local and regional tumor, followed (or preceded) by a combination of chemotherapy, radiotherapy, endocrine (hormone) therapy, and targeted therapy. Research is ongoing for the use of immunotherapy in breast cancer management.

Management of breast cancer is undertaken by a multidisciplinary team, including medical-, radiation-, and surgical- oncologists, and is guided by national and international guidelines. Factors such as treatment, oncologist, hospital and stage of your breast cancer decides the cost of breast cancer one must pay.

Staging

Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.^[1][2] Cancer that has spread beyond the breast and the lymph nodes is classified as Stage IV, or metastatic cancer, and requires mostly systemic treatment.

The TNM staging system of a cancer is a measurement of the physical extent of the tumor and its spread, where:

• T stands for the main (primary) tumor (range of T0-T4)
• N stands for spread to nearby lymph nodes (range of N0-N3)
• M stands for metastasis (spread to distant parts of the body; either M0 or M1)

If the stage is based on removal of the cancer with surgery and review by the pathologist, the letter p (for pathologic) or yp (pathologic after neoadjuvant therapy) may appear before the T and N letters. If the stage is based on clinical assessment using physical exam and imaging, the letter c (for clinical) may appear. The TNM information is then combined to give the cancer an overall stage. Stages are expressed in Roman numerals from stage I (the least advanced stage) to stage IV (the most advanced stage). Non-invasive cancer (carcinoma in situ) is listed as stage 0.^[3]

TNM staging, in combination with histopathology, grade and genomic profiling, is used for the purpose of prognosis,^[4] and to determine whether additional treatment is warranted.^[5]

Classification

Main article: Breast cancer classification

Breast cancer is classified into three major subtypes for the purpose of predicting ^[4] response to treatment. These are determined by the presence or absence of receptors on the cells of the tumor. The three major subgroups are:

• Luminal-type, which are tumors positive for hormone receptors (estrogen or progesterone receptor). This subtype suggests a response to endocrine therapy.
• HER2-type, which are positive for over-expression of the HER2 receptor. ER and PR can be positive or negative. This subtype receives targeted therapy.
• Basal-type, or Triple Negative (TN), which are negative for all three major receptor types

Additional classification schema are used for prognosis and include histopathology, grade, stage, and genomic profiling.

Surgery

 

Excised breast tissue showing a stellate, pale area of cancer measuring 2 cm across. The tumor could be felt as a hard, mobile lump before the surgical excision.

Surgery is the primary management for breast cancer. Depending on staging and biologic characteristics of the tumor, surgery can be a lumpectomy (removal of the lump only), a mastectomy, or a modified radical mastectomy. Lymph nodes are often included in the scope of breast tumor removal. Surgery can be performed before or after receiving systemic therapy. Women who test positive for faulty BRCA1 or BRCA2 genes can choose to have risk-reducing surgery before the cancer appears.^[6][7]

Lumpectomy techniques are increasingly utilized for breast-conservation cancer surgery. Studies indicate that for patients with a single tumor smaller than 4 cm, a lumpectomy with negative surgical margins may be as effective as a mastectomy.^[8] Prior to a lumpectomy, a needle-localization of the lesion with placement of a guidewire may be performed, sometimes by an interventional radiologist if the area being removed was detected by mammography or ultrasound, and sometimes by the surgeon if the lesion can be directly palpated.

However, mastectomy may be the preferred treatment in certain instances:

• Two or more tumors exist in different areas of the breast (a "multifocal" cancer)
• The breast has previously received radiotherapy
• The tumor is large relative to the size of the breast
• The patient has had scleroderma or another disease of the connective tissue, which can complicate radiotherapy
• The patient lives in an area where radiotherapy is inaccessible
• The patient wishes to avoid systemic therapy
• The patient is apprehensive about the risk of local recurrence after lumpectomy

Specific types of mastectomy can also include: skin-sparing, nipple-sparing, subcutaneous, and prophylactic.

Standard practice requires the surgeon to establish that the tissue removed in the operation has margins clear of cancer, indicating that the cancer has been completely excised. Additional surgery may be necessary if the removed tissue does not have clear margins, sometimes requiring removal of part of the pectoralis major muscle, which is the main muscle of the anterior chest wall.

During the operation, the lymph nodes in the axilla are also considered for removal. In the past, large axillary operations took out 10 to 40 nodes to establish whether cancer had spread. This had the unfortunate side effect of frequently causing lymphedema of the arm on the same side, as the removal of this many lymph nodes affected lymphatic drainage. More recently, the technique of sentinel lymph node (SLN) dissection has become popular, as it requires the removal of far fewer lymph nodes, resulting in fewer side effects while achieving the same 10-year survival as its predecessor.^[9] The sentinel lymph node is the first node that drains the tumor, and subsequent SLN mapping can save 65–70% of patients with breast cancer from having a complete lymph node dissection for what could turn out to be a negative nodal basin. Advances in SLN mapping over the past decade have increased the accuracy of detecting Sentinel Lymph Node from 80% using blue dye alone to between 92% and 98% using combined modalities.^[10] SLN biopsy is indicated for patients with T1 and T2 lesions (<5 cm) and carries a number of recommendations for use on patient subgroups.^[10] Recent trends continue to favor less radical axillar node resection even in the presence of some metastases in the sentinel node.^[11]

A meta-analysis has found that in people with operable primary breast cancer, compared to being treated with axillary lymph node dissection, being treated with lesser axillary surgery (such as axillary sampling or sentinel lymph node biopsy) does not lessen the chance of survival. Overall survival is slightly reduced by receiving radiotherapy alone when compared to axillary lymph node dissection. In the management of primary breast cancer, having no axillary lymph nodes removed is linked to increased risk of regrowth of cancer. Treatment with axillary lymph node dissection has been found to give an increased risk of lymphoedema, pain, reduced arm movement and numbness when compared to those treated with sentinel lymph node dissection or no axillary surgery.^[12]

Ovary removal

Prophylactic oophorectomy may be prudent in women who are at a high risk for recurrence or are seeking an alternative to endocrine therapy as it removes the primary source of estrogen production in pre-menopausal women. Women who are carriers of a BRCA mutation have an increased risk of both breast and ovarian cancers and may choose to have their ovaries removed prophylactically as well.^[13]

Breast reconstruction

Main article: Breast reconstruction

Breast reconstruction surgery is the rebuilding of the breast after breast cancer surgery, and is included in holistic approaches to cancer management to address identity and emotional aspects of the disease. Reconstruction can take place at the same time as cancer-removing surgery, or months to years later. Some women decide not to have reconstruction or opt for a prosthesis instead.

Investigational surgical management

Cryoablation is an experimental therapy available for women with small or early-stage breast cancer. The treatment freezes, then defrosts tumors using small needles so that only the harmful tissue is damaged and ultimately dies.^[14] This technique may provide an alternative to more invasive surgeries, potentially limiting side effects.^[15]

Radiation therapy

Radiation therapy is an adjuvant treatment for most women who have undergone lumpectomy and for some women who have mastectomy surgery. In these cases the purpose of radiation is to reduce the chance that the cancer will recur locally (within the breast or axilla). Radiation therapy involves using high-energy X-rays or gamma rays that target a tumor or post surgery tumor site. This radiation is very effective in killing cancer cells that may remain after surgery or recur where the tumor was removed.

Radiation therapy can be delivered by external beam radiotherapy, brachytherapy (internal radiotherapy), or by intra-operative radiotherapy (IORT). In the case of external beam radiotherapy, X-rays are delivered from outside the body by a machine called a Linear Accelerator or Linac. In contrast, brachytherapy involves the precise placement of radiation source(s) directly at the treatment site. IORT includes a one-time dose of radiation administered with breast surgery. Radiation therapy is important in the use of breast-conserving therapy because it reduces the risk of local recurrence.

Radiation therapy eliminates the microscopic cancer cells that may remain near the area where the tumor was surgically removed. The dose of radiation must be strong enough to ensure the elimination of cancer cells. However, radiation affects normal cells and cancer cells alike, causing some damage to the normal tissue around where the tumor was. Healthy tissue can repair itself, while cancer cells do not repair themselves as well as normal cells. For this reason, radiation treatments are given over an extended period, enabling the healthy tissue to heal. Treatments using external beam radiotherapy are typically given over a period of five to seven weeks, performed five days a week. Recent large trials (UK START and Canadian) have confirmed that shorter treatment courses, typically over three to four weeks, result in equivalent cancer control and side effects as the more protracted treatment schedules. Each treatment takes about 15 minutes. A newer approach, called 'accelerated partial breast irradiation' (APBI), uses brachytherapy to deliver the radiation in a much shorter period of time. APBI delivers radiation to only the immediate region surrounding the original tumor^[16][17][18] and can typically be completed over the course of one week.^[16]

Indications for radiation

Radiation treatment is mainly effective in reducing the risk of local relapse in the affected breast. Therefore, it is recommended in most cases of breast conserving surgeries and less frequently after mastectomy. Indications for radiation treatment are constantly evolving. Patients treated in Europe have been more likely in the past to be recommended adjuvant radiation after breast cancer surgery as compared to patients in North America. Radiation therapy is usually recommended for all patients who had lumpectomy, quadrant-resection. Radiation therapy is usually not indicated in patients with advanced (stage IV disease) except for palliation of symptoms like bone pain or fungating lesions.

In general recommendations would include radiation:

• As part of breast conserving therapy.
• After mastectomy for patients with higher risk of recurrence because of conditions such as a large primary tumor or substantial involvement of the lymph nodes.^[19]

Other factors which may influence adding adjuvant radiation therapy:

• Tumor close to or involving the margins on pathology specimen
• Multiple areas of tumor (multicentric disease)
• Microscopic invasion of lymphatic or vascular tissues
• Microcopic invasion of the skin, nipple/areola, or underlying pectoralis major muscle
• Patients with extension out of the substance of a LN
• Inadequate numbers of axillary LN sampled

Types of radiotherapy

 

The SAVI applicator is a multiple catheter breast brachytherapy device.

See also: Brachytherapy

Radiotherapy can be delivered in many ways but is most commonly produced by a linear accelerator.

This usually involves treating the whole breast in the case of breast lumpectomy or the whole chest wall in the case of mastectomy. Lumpectomy patients with early-stage breast cancer may be eligible for a newer, shorter form of treatment called "breast brachytherapy". This approach allows physicians to treat only part of the breast in order to spare healthy tissue from unnecessary radiation.

Improvements in computers and treatment delivery technology have led to more complex radiotherapy treatment options. One such new technology is using IMRT (intensity modulated radiation therapy), which can change the shape and intensity of the radiation beam making "beamlets" at different points across and inside the breast. This allows for better dose distribution within the breast while minimizing dose to healthy organs such as the lung or heart.^[20] However, there is yet to be a demonstrated difference in treatment outcomes (both tumor recurrence and level of side effects) for IMRT in breast cancer when compared to conventional radiotherapy treatment. In addition, conventional radiotherapy can also deliver similar dose distributions utilizing modern computer dosimetry planning and equipment. External beam radiation therapy treatments for breast cancer are typically given every day, five days a week, for five to 10 weeks.^[21]

Within the past decade, a new approach called accelerated partial breast irradiation (APBI) has gained popularity. APBI is used to deliver radiation as part of breast conservation therapy. It treats only the area where the tumor was surgically removed, plus adjacent tissue. APBI reduces the length of treatment to just five days, compared to the typical six or seven weeks for whole breast irradiation.

APBI treatments can be given as brachytherapy or external beam with a linear accelerator. These treatments are usually limited to women with well-defined tumors that have not spread.^[22] A meta-analysis of randomised trials of partial breast irradiation (PBI) vs. whole breast irradiation (WBI) as part of breast conserving therapy demonstrated a reduction in non-breast-cancer and overall mortality.^[23]

In breast brachytherapy, the radiation source is placed inside the breast, treating the cavity from the inside out. There are several different devices that deliver breast brachytherapy. Some use a single catheter and balloon to deliver the radiation. Other devices utilize multiple catheters to deliver radiation.

A study is currently underway by the National Surgical Breast and Bowel Project (NSABP) to determine whether limiting radiation therapy to only the tumor site following lumpectomy is as effective as radiating the whole breast.

New technology has also allowed more precise delivery of radiotherapy in a portable fashion — for example in the operating theatre. Targeted intraoperative radiotherapy (TARGIT)^[24] is a method of delivering therapeutic radiation from within the breast using a portable X-ray generator called Intrabeam.

The TARGIT-A trial was an international randomised controlled non-inferiority phase III clinical trial led from University College London. 28 centres in 9 countries accrued 2,232 patients to test whether TARGIT can replace the whole course of radiotherapy in selected patients.^[25] The TARGIT-A trial results found that the difference between the two treatments was 0.25% (95% CI -1.0 to 1.5) i.e., at most 1.5% worse or at best 1.0% better with single dose TARGIT than with standard course of several weeks of external beam radiotherapy.^[26] In the TARGIT-B trial, as the TARGIT technique is precisely aimed and given immediately after surgery, in theory it could be able provide a better boost dose to the tumor bed as suggested in phase II studies.^[27]

Systemic therapy

 

Nolvadex (tamoxifen) 20 mg tablets (UK)

Systemic therapy uses medications to treat cancer cells throughout the body. Any combination of systemic treatments may be used to treat breast cancer. Standard of care systemic treatments include chemotherapy, endocrine therapy and targeted therapy.

Chemotherapy

See also: Breast cancer chemotherapy

Chemotherapy (drug treatment for cancer) may be used before surgery, after surgery, or instead of surgery for those cases in which surgery is considered unsuitable. Chemotherapy is justified for cancers whose prognosis after surgery is poor without additional intervention.

Hormonal therapy

See also: Hormonal therapy (oncology)

Patients with estrogen receptor positive tumors are candidates for receiving endocrine therapy to reduce chance of relapse or of a new primary breast cancer. Endocrine therapy is usually administered after surgery, chemotherapy and radiotherapy have been given, but can also occur in the neoadjuvant or non-surgical setting. Hormonal treatments include:

• Tamoxifen is typically given to premenopausal women to inhibit activity of estrogen receptors.
• Aromatase inhibitors are typically given to postmenopausal women to lower the amount of bioavailable estrogen in their systems.
• GnRH analogues for ovarian suppression are beneficial in women who remain premenopausal and are at sufficient risk for recurrence to warrant adjuvant chemotherapy.^[28]
• Estrogen cycling was reported at the 31st annual San Antonio Breast Cancer Symposium. About a third of the 66 participants - women with metastatic breast cancer that had developed resistance to standard estrogen-lowering therapy - a daily dose of estrogen could stop the growth of their tumors or even cause them to shrink. If study participants experienced disease progression on estrogen, they could go back to an aromatase inhibitor that they were previously resistant to and see a benefit - their tumors were once again inhibited by estrogen deprivation. That effect sometimes wore off after several months, but then the tumors might again be sensitive to estrogen therapy. In fact, some patients have cycled back and forth between estrogen and an aromatase inhibitor for several years. PET (positron emission tomography) scans before starting estrogen and again 24 hours later predicted those tumors which responded to estrogen therapy: the responsive tumors showed an increased glucose uptake, called a PET flare. The mechanism of action is uncertain, although estrogen reduces the amount of a tumor-promoting hormone called insulin-like growth factor-1 (IGF1).^{[29][unreliable medical source?]}
• Anabolic steroids such as testosterone, fluoxymesterone, drostanolone propionate, epitiostanol, and mepitiostane have historically been used to treat breast cancer because of their antiestrogenic effects in the breasts but are now rarely if ever used due to their virilizing side effects.^[30]

• v
• t
• e

Estrogen dosages for breast cancer

Route/form	Estrogen	Dosage	Ref(s)
Oral	Estradiol	10 mg 3x/day AI-resistant: 2 mg 1–3x/day	^[31]^[32] ^[31]^[33]
	Estradiol valerate	AI-resistant: 2 mg 1–3x/day	^[31]^[33]
	Conjugated estrogens	10 mg 3x/day	^[34]^[35]^[36]^[37]
	Ethinylestradiol	0.5–1 mg 3x/day	^[35]^[31]^[38]^[37]
	Diethylstilbestrol	5 mg 3x/day	^[35]^[39]^[40]
	Dienestrol	5 mg 3x/day	^[38]^[37]^[40]
	Dimestrol	30 mg/day	^[34]^[37]^[40]
	Chlorotrianisene	24 mg/day	^[34]^[40]
IM or SC injection	Estradiol benzoate	5 mg 2–3x/week	^[38]^[41]^[39]^[42]
	Estradiol dipropionate	5 mg 2–3x/week	^[38]^[39]^[43]^[42]
	Estradiol valerate	30 mg 1x/2 weeks	^[41]
	Polyestradiol phosphate	40–80 mg 1x/4 weeks	^[44]^[45]
	Estrone	5 mg ≥3x/week	^[46]
Notes: (1) Only in women who are at least 5 years postmenopausal.^[31] (2) Dosages are not necessarily equivalent.

• v
• t
• e

Androgen/anabolic steroid dosages for breast cancer

Route	Medication	Form	Dosage
Oral	Methyltestosterone	Tablet	30–200 mg/day
	Fluoxymesterone	Tablet	10–40 mg 3x/day
	Calusterone	Tablet	40–80 mg 4x/day
	Normethandrone	Tablet	40 mg/day
Buccal	Methyltestosterone	Tablet	25–100 mg/day
Injection (IM or SC)	Testosterone propionate	Oil solution	50–100 mg 3x/week
	Testosterone enanthate	Oil solution	200–400 mg 1x/2–4 weeks
	Testosterone cypionate	Oil solution	200–400 mg 1x/2–4 weeks
	Mixed testosterone esters	Oil solution	250 mg 1x/week
	Methandriol	Aqueous suspension	100 mg 3x/week
	Androstanolone (DHT)	Aqueous suspension	300 mg 3x/week
	Drostanolone propionate	Oil solution	100 mg 1–3x/week
	Metenolone enanthate	Oil solution	400 mg 3x/week
	Nandrolone decanoate	Oil solution	50–100 mg 1x/1–3 weeks
	Nandrolone phenylpropionate	Oil solution	50–100 mg/week
Note: Dosages are not necessarily equivalent. Sources: See template.

Targeted therapy

See also: Targeted therapy

In patients whose cancer expresses an over-abundance of the HER2 protein, a monoclonal antibody known as trastuzumab (Herceptin) is used to block the activity of the HER2 protein in breast cancer cells, slowing their growth. In the advanced cancer setting, trastuzumab use in combination with chemotherapy can both delay cancer growth as well as improve the recipient's survival.^[47] Pertuzumab may work synergistically with trastuzumab on the expanded EGFR family of receptors, although it is currently only standard of care for metastatic disease.

Neratinib has been approved by the FDA for extended adjuvant treatment of early stage HER2-positive breast cancer.^[48]

PARP inhibitors are used in the metastatic setting, and are being investigated for use in the non-metastatic setting through clinical trials.

Approved antibody-drug conjugates: trastuzumab emtansine (2013), trastuzumab deruxtecan (2019), sacituzumab govitecan (2020).

Treatment response assessment

Medical imaging

Managing side effects

Drugs and radiotherapy given for cancer can cause unpleasant side effects such as nausea and vomiting, mouth sores, dermatitis, and menopausal symptoms. Around a third of patients with cancer use complementary therapies, including homeopathic medicines, to try to reduce these side effects.^{[49][unreliable medical source?]}

Insomnia

It was believed that one would find a bi-directional relationship between insomnia and pain, but instead it was found that trouble sleeping was more likely a cause, rather than a consequence, of pain in patients with cancer. An early intervention to manage sleep would overall relieve patient with side effects.^{[50][unreliable medical source?]}

Approximately 40 percent of menopausal women experience sleep disruption, often in the form of difficulty with sleep initiation and frequent nighttime awakenings. There is a study, first to show sustained benefits in sleep quality from gabapentin, which Rochester researchers already have demonstrated alleviates hot flashes.^{[51][unreliable medical source?]}

Hot flushes

Lifestyle adjustments are usually suggested first to manage hot flushes (or flashes) due to endocrine therapy.^[52] This can include avoiding triggers such as alcohol, caffeine and smoking. If hot flashes continue, and depending on their frequency and severity, several drugs can be effective in some patients, in particular SNRIs such as venlafaxine, also oxybutinin and others.

Complementary medicines that contain phytoestrogens are not recommended for breast cancer patients as they may stimulate oestrogen receptor-positive tumours.^[53]

Lymphedema

Some patients develop lymphedema, as a result of axillary node dissection or of radiation treatment to the lymph nodes.^[54] Although traditional recommendations limited exercise, a new study shows that participating in a safe, structured weight-lifting routine can help women with lymphedema take control of their symptoms and reap the many rewards that resistance training has on their overall health as they begin life as a cancer survivor. It recommends that women start with a slowly progressive program, supervised by a certified fitness professional, in order to learn how to do these types of exercises properly. Women with lymphedema should also wear a well-fitting compression garment during all exercise sessions.^{[55][unreliable medical source?]}

Upper-limb dysfunction

Upper-limb dysfunction is a common side effect of breast cancer treatment.^[56] Shoulder range of motion can be impaired after surgery. Exercise can meaningfully improve should range of motion in women with breast cancer.^[56] An exercise programme can be started early after surgery, if it does not negatively affect wound drainage.^[56][57][58]

Side effects of radiation therapy

External beam radiation therapy is a non-invasive treatment with some short term and some longer-term side effects. Patients undergoing some weeks of treatment usually experience fatigue caused by the healthy tissue repairing itself and aside from this there can be no side effects at all. However many breast cancer patients develop a suntan-like change in skin color in the exact area being treated. As with a suntan, this darkening of the skin usually returns to normal in the one to two months after treatment. In some cases permanent changes in color and texture of the skin is experienced. Other side effects sometimes experienced with radiation can include:

• muscle stiffness
• mild swelling
• tenderness in the area
• lymphedema

After surgery, radiation and other treatments have been completed, many patients notice the affected breast seems smaller or seems to have shrunk. This is basically due to the removal of tissue during the lumpectomy operation.

The use of adjuvant radiation has significant potential effects if the patient has to later undergo breast reconstruction surgery. Fibrosis of chest wall skin from radiation negatively affects skin elasticity and makes tissue expansion techniques difficult. Traditionally most patients are advised to defer immediate breast reconstruction when adjuvant radiation is planned and are most often recommended surgery involving autologous tissue reconstruction rather than breast implants.

Studies suggest APBI may reduce the side effects associated with radiation therapy, because it treats only the tumor cavity and the surrounding tissue. In particular, a device that uses multiple catheters and allows modulation of the radiation dose delivered by each of these catheters has been shown to reduce harm to nearby, healthy tissue.^[59]

See also

• ALMANAC, Axillary Lymphatic Mapping Against Nodal Axillary Clearance trial

References

1. "Breast Cancer – Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual". cancerstaging.org. Retrieved 8 August 2017.
2. "Breast Cancer Gene Expression Tests". American Cancer Society. 18 August 2016.
3. "Breast Cancer Staging, 7th Edition" (PDF). American Joint Committee on Cancer. 2009.
4. Italiano A (December 2011). "Prognostic or predictive? It's time to get back to definitions!". Journal of Clinical Oncology. 29 (35): 4718, author reply 4718–9. doi:10.1200/JCO.2011.38.3729. PMID 22042948.
5. "Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast" (PDF). College of American Pathologists. June 2012.
6. "Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 7 December 2021. doi:10.3310/alert_48318.
7. Marcinkute, Ruta; Woodward, Emma Roisin; Gandhi, Ashu; Howell, Sacha; Crosbie, Emma J; Wissely, Julie; Harvey, James; Highton, Lindsay; Murphy, John; Holland, Cathrine; Edmondson, Richard; Clayton, Richard; Barr, Lester; Harkness, Elaine F; Howell, Anthony (10 February 2021). "Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers". Journal of Medical Genetics. 59 (2): 133–140. doi:10.1136/jmedgenet-2020-107356. ISSN 0022-2593. PMID 33568438. S2CID 231876899.
8. "Mastectomy vs. Lumpectomy". Breastcancer.org. 9 June 2013. Retrieved 23 October 2013.
9. Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. (September 2016). "Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial". Annals of Surgery. 264 (3): 413–20. doi:10.1097/SLA.0000000000001863. PMC 5070540. PMID 27513155.
10. Bennett, Joseph J. (2006). "Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma". US Oncological Disease. 1 (1): 16–19. Retrieved 23 October 2013.
11. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. (February 2011). "Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial". JAMA. 305 (6): 569–75. doi:10.1001/jama.2011.90. PMC 5389857. PMID 21304082.
12. Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW (January 2017). "Axillary treatment for operable primary breast cancer". The Cochrane Database of Systematic Reviews. 1 (5): CD004561. doi:10.1002/14651858.cd004561.pub3. PMC 6464919. PMID 28052186.
13. "Prophylactic Ovary Removal | Breastcancer.org". Breastcancer.org. Retrieved 8 August 2017.
14. Gray, Richard (9 December 2012). . The Telegraph. Archived from the original on 10 December 2012. Retrieved 24 October 2013.
15. "Cryotherapy | Breastcancer.org". Breastcancer.org. Retrieved 8 August 2017.
16. Nelson JC, Beitsch PD, Vicini FA, Quiet CA, Garcia D, Snider HC, et al. (July 2009). "Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial". American Journal of Surgery. 198 (1): 83–91. doi:10.1016/j.amjsurg.2008.09.016. PMID 19268900.
17. Keisch; et al. (February 2007). "American Brachytherapy Society breast brachytherapy task group" (PDF). American Brachytherapy Society. Retrieved 25 September 2009.
18. Polgár C, Major T (February 2009). "Current status and perspectives of brachytherapy for breast cancer". International Journal of Clinical Oncology. 14 (1): 7–24. doi:10.1007/s10147-008-0867-y. PMID 19225919. S2CID 20971836.
19. . RT Answers. Archived from the original on 10 May 2013. Retrieved 23 October 2013.
20. . RT Answers. Archived from the original on 6 October 2013. Retrieved 23 October 2013.
21. . RT Answers. Archived from the original on 10 May 2013. Retrieved 23 October 2013.
22. . RT Answers. Archived from the original on 28 September 2011. Retrieved 23 October 2013.
23. Vaidya JS, Bulsara M, Wenz F, Coombs N, Singer J, Ebbs S, et al. (October 2016). "Reduced Mortality With Partial-Breast Irradiation for Early Breast Cancer: A Meta-Analysis of Randomized Trials". International Journal of Radiation Oncology, Biology, Physics. 96 (2): 259–265. doi:10.1016/j.ijrobp.2016.05.008. PMID 27478165.
24. Vaidya J. "TARGIT (TARGeted Intraoperative radioTherapy)". Retrieved 11 March 2007.
25. Vaidya J, Tobias J, Baum M, Houghton J. "Protocol 99PRT/47 Targeted Intraoperative radiotherapy (Targit) for breast cancer". Retrieved 11 March 2007.
26. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. (July 2010). "Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial". Lancet (Submitted manuscript). 376 (9735): 91–102. doi:10.1016/S0140-6736(10)60837-9. PMID 20570343. S2CID 2385098.
27. Vaidya JS, Baum M, Tobias JS, Massarut S, Wenz F, Murphy O, et al. (December 2006). "Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost". International Journal of Radiation Oncology, Biology, Physics. 66 (5): 1335–8. doi:10.1016/j.ijrobp.2006.07.1378. PMID 17084562.
28. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. (January 2015). "Adjuvant ovarian suppression in premenopausal breast cancer". The New England Journal of Medicine. 372 (5): 436–46. doi:10.1056/NEJMoa1412379. PMC 4341825. PMID 25495490.
29. "Women With Metastatic Breast Cancer Can Benefit From Estrogen Pills". Medical News Today. 12 December 2008. Retrieved 23 October 2013.
30. Michael Clinton Perry (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 368–. ISBN 978-0-7817-7328-7.
31. Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). "The use of high-dose estrogens for the treatment of breast cancer". Maturitas. 95: 11–23. doi:10.1016/j.maturitas.2016.10.010. PMID 27889048.
32. "ESTRACE® TABLETS (estradiol tablets, USP) FDA label" (PDF). 2005.
33. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ (January 2014). "Breast cancer: current and future endocrine therapies". Mol. Cell. Endocrinol. 382 (1): 695–723. doi:10.1016/j.mce.2013.08.001. PMID 23933149.
34. Green RB, Sethi RS, Lindner HH (July 1964). "Treatment of advanced carcinoma of the breast: Progress in therapy during the past decade". Am. J. Surg. 108: 107–21. doi:10.1016/0002-9610(64)90094-7. PMID 14182428.
35. Thomas JA, Keenan EJ (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
36. "Premarin® (conjugated estrogens tablets, USP) FDA label" (PDF). 2003.
37. Van Winkle W (1949). "Council on Pharmacy and Chemistry. Estrogens and Androgens in Mammary Cancer". JAMA: The Journal of the American Medical Association. 140 (15): 1214. doi:10.1001/jama.1949.02900500022007. ISSN 0098-7484.
38. Kahr E (1966). "Die Allgemeinbehandlung" [General Treatment]. Der Inoperable Krebskranke: Möglichkeiten der Therapie in Klinik und Praxis [The Inoperable Cancer Patient: Possibilities of Therapy in Clinic and Practice]. Springer-Verlag. pp. 104–155. doi:10.1007/978-3-642-86140-6_4. ISBN 978-3-642-86140-6.
39. Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli, David G. Johns (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
40. Nathanson IT, Kelley RM (January 1952). "Hormonal treatment of cancer". N. Engl. J. Med. 246 (5): 180–9, concl. doi:10.1056/NEJM195201312460505. PMID 14890833.
41. Dobson L (August 1962). "The management of metastatic breast cancer". Surg. Clin. North Am. 42: 861–76. doi:10.1016/S0039-6109(16)36728-7. PMID 13886800.
42. Martz G (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 39–. ISBN 978-3-642-86282-3.
43. Committee on Research, AMA (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four patients". Journal of the American Medical Association. 172 (12): 1271. doi:10.1001/jama.1960.03020120049010. ISSN 0002-9955.
44. . Pharmanovia.
45. Ostrowski MJ, Jackson AW (1979). "Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma". Cancer Treat Rep. 63 (11–12): 1803–7. PMID 393380.
46. "Estrone suspension FDA review" (PDF). 1979.
47. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. (March 2001). "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2". The New England Journal of Medicine. 344 (11): 783–92. doi:10.1056/NEJM200103153441101. PMID 11248153.
48. Research, Center for Devices and Radiological Health, Center for Drug Evaluation. "Approved Drugs - FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer". www.fda.gov. Retrieved 8 August 2017.
49. "Can Homeopathic Medicines Help Relieve The Side-Effects Of Cancer Therapy?". Medical News Today. 15 April 2009. Retrieved 24 October 2013.
50. "Treating Sleep Problems May Improve Pain Management In Patients With Cancer". Medical News Today. 16 April 2009. Retrieved 24 October 2013.
51. "Sleep For Women With Hot Flashes Enhanced By Seizure Drug". Medical News Today. 9 September 2009. Retrieved 24 October 2013.
52. See for example a review by Kligman and Younus Kligman L, Younus J (February 2010). "Management of hot flashes in women with breast cancer". Current Oncology. 17 (1): 81–6. doi:10.3747/co.v17i1.473. PMC 2826783. PMID 20179808.
53. For example National Prescribing Service NPS MedicineWise . Archived from the original on 26 August 2014. Retrieved 24 August 2014. | Published in Health News and Evidence 14 July 2014 | retrieved 25 August 2014
54. "Causes, incidence, and risk factors". Lymphatic obstruction. U.S. National Library of Medicine. 3 September 2012. Retrieved 23 October 2013.
55. "Lifting Weights Reduces Lymphedema Symptoms Following Breast Cancer Surgery". Medical News Today. 13 August 2009. Retrieved 23 October 2013.
56. McNeely ML, Campbell K, Ospina M, Rowe BH, Dabbs K, Klassen TP, et al. (June 2010). "Exercise interventions for upper-limb dysfunction due to breast cancer treatment". The Cochrane Database of Systematic Reviews (6): CD005211. doi:10.1002/14651858.CD005211.pub2. PMID 20556760.
57. "Exercise programme improves arm function and pain after breast cancer surgery". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 26 September 2022. doi:10.3310/nihrevidence_53632. S2CID 252562000.
58. Bruce, Julie; Mazuquin, Bruno; Mistry, Pankaj; Rees, Sophie; Canaway, Alastair; Hossain, Anower; Williamson, Esther; Padfield, Emma J; Lall, Ranjit; Richmond, Helen; Chowdhury, Loraine; Lait, Clare; Petrou, Stavros; Booth, Katie; Lamb, Sarah E (February 2022). "Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT". Health Technology Assessment. 26 (15): 1–124. doi:10.3310/JKNZ2003. ISSN 1366-5278. PMID 35220995. S2CID 247157545.
59. Yashar CM, Blair S, Wallace A, Scanderbeg D (1 October 2009). "Initial clinical experience with the Strut-Adjusted Volume Implant brachytherapy applicator for accelerated partial breast irradiation". Brachytherapy. 8 (4): 367–72. doi:10.1016/j.brachy.2009.03.190. PMID 19744892.

External links

• Breast cancer at Curlie
• Prevention and treatment of breast cancer by suppressing aromatase activity and expression